CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization.

0

CIRM-Funded Clinical Trials

Photo Credit: UCLA Broad Stem Cell Research Center

Funding Opportunities

Visit our Funding Opportunities page to apply for clinical trial research funding.

Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
Arthritis
Osteoarthritis
Dr. Kristen A Johnson Calibr Phase 1 Completed 60
Bladder or Urinary Tract Disorder James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Blood Cancer
Solid Tumors
Professor Irving L Weissman MD Stanford University Phase 1 Completed 88
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss
Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
COVID-19
Respiratory Disorders
Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
COVID-19
Respiratory Disorders
William van der Touw Celularity Inc. Phase 1/2 Closed 86
Cystinosis
Kidney Failure
Dr. Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
Danon Disease
Pediatrics
Dr. Jonathan Schwartz Rocket Pharmaceuticals, Inc. Phase 2 Launching N/A
Developmental Disorders
Spina Bifida
Dr. Diana L. Farmer University of California, Davis Phase 2 Recruiting 55
Genetic Disorder
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
Dr. Donald B. Kohn
Leslie Meltzer
University of California, Los Angeles
Orchard Therapeutics
Phase 2 Completed 10
HIV/AIDS
Immune Disease
Steven G. Deeks University of California, San Francisco Phase 1/2 Recruiting 18
Immune Disease
Pediatrics
X-linked Chronic Granulomatous Disease
Dr. Donald B. Kohn University of California, Los Angeles Phase 1/2 Recruiting 16
Immune Disease
Severe Combined Immunodeficiency, X-linked (X-SCID)
Stephen Gottschalk St. Jude Children’s Research Hospital Phase 1/2 Suspended 28
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, X-linked (X-SCID)
Dr. Judith A Shizuru
Wendy Pang
Stanford University
Jasper Therapeutics, Inc.
Phase 1/2 Recruiting 40
Immune Disease Dr. Jonathan Benjamin ImmPACT-Bio, Inc. Phase 1/2 Launching N/A
Immune Disease
Leukocyte Adhesion Deficiency
Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Completed 9
Immune Disease Maria Grazia Roncarolo Tr1X Inc. Phase 1 Launching N/A
Lupus, Systemic Lupus Erythematosus (SLE) Dr. Vaneet Sandhu Fate Therapeutics, Inc. Phase 1 Launching N/A
Muscle Injury Peter C Belafsky University of California, Davis Phase 1/2 Recruiting 62
Neurological Disorders
Other
Prof. Olivia Kim-McManus University of California, San Diego Phase 1/2 Launching N/A
Pediatrics
Sickle Cell Disease
Dr. Donald B. Kohn University of California, Los Angeles Phase 1 Active, not recruiting 4
Pulmonary Hypertension
Vascular Disease
Dr. Michael I Lewis Cedars-Sinai Medical Center Phase 1/2 Completed 26
Solid Tumors Dr. Dennis J Slamon University of California, Los Angeles Phase 1 Completed 46